Tandem Diabetes Care Inc (TNDM)
47.30
+0.38
(+0.80%)
USD |
NASDAQ |
May 17, 16:00
47.30
0.00 (0.00%)
After-Hours: 20:00
Tandem Diabetes Care Research and Development Expense (Annual): 169.67M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 169.67M |
| December 31, 2022 | 139.11M |
| December 31, 2021 | 92.05M |
| December 31, 2020 | 63.57M |
| December 31, 2019 | 45.20M |
| December 31, 2018 | 29.23M |
| December 31, 2017 | 20.66M |
| Date | Value |
|---|---|
| December 31, 2016 | 18.81M |
| December 31, 2015 | 16.96M |
| December 31, 2014 | 15.79M |
| December 31, 2013 | 11.08M |
| December 31, 2012 | 9.009M |
| December 31, 2011 | 8.261M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
45.20M
Minimum
2019
169.67M
Maximum
2023
101.92M
Average
92.05M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Insulet Corp | 205.00M |
| Abbott Laboratories | 2.741B |
| Stryker Corp | 1.388B |
| Twist Bioscience Corp | 106.89M |
| Perspective Therapeutics Inc | 21.31M |